As of June, 13 Summit Therapeutics plc (SMMT) EPS Estimated At $-0.76

May 17, 2018 - By Mary Markley

Summit Therapeutics plc (NASDAQ:SMMT) Corporate Logo

On June, 13 WallStreet awaited Summit Therapeutics plc (NASDAQ:SMMT)’s earnings report, RTT reports. earnings per share of $-0.76 is 52.00 % down from 2017’s $-0.5 EPS. -33.91 % EPS growth is what Wall Street’s predicts after $-1.15 reported EPS last quarter. SMMT is reaching $13.95 during the last trading session, after increased 1.82%.Summit Therapeutics plc is uptrending after having risen 4.52% since May 17, 2017. SMMT has 79,366 volume or 105.88% up from normal. SMMT underperformed the S&P500 by 7.03%.

Summit Therapeutics plc (NASDAQ:SMMT) Ratings Coverage

In total 8 analysts cover Summit Therapeutics plc – American Depositary Shares (NASDAQ:SMMT). “Buy” rating has 8, “Sell” are 0, while 0 are “Hold”. (NASDAQ:SMMT) has 100% bullish analysts. 10 are the (NASDAQ:SMMT)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. On Friday, December 1 the rating was reinitiated by H.C. Wainwright with “Buy”. In Tuesday, March 6 report Canaccord Genuity maintained it with “Buy” rating and $28.0 target. In Wednesday, April 11 report Canaccord Genuity maintained the stock with “Buy” rating. On Friday, April 13 the stock of Summit Therapeutics plc (NASDAQ:SMMT) earned “Buy” rating by SunTrust. On Friday, January 26 the stock has “Outperform” rating by Oppenheimer.

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America.The firm is valued at $218.72 million. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection (CDI).Currently it has negative earnings. The companyÂ’s lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease.

For more Summit Therapeutics plc (NASDAQ:SMMT) news released briefly go to: Globenewswire.com, Nasdaq.com, Globenewswire.com, Benzinga.com or Globenewswire.com. The titles are as follows: “Summit Therapeutics plc : Notice of AGM” released on May 03, 2018, “Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea in Late …” on April 23, 2018, “Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial” with a publish date: April 19, 2018, “Summit Therapeutics’ Upcoming Duchenne Muscular Dystrophy Data ‘A Strong Catalyst,’ Janney Says In Bullish Initiation” and the last “Summit Therapeutics plc : Total voting rights” with publication date: May 01, 2018.

Summit Therapeutics plc (NASDAQ:SMMT) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: